-
1Academic Journal
Συγγραφείς: Сухорукова, Алена, Шутова, Светлана
Θεματικοί όροι: ГЛАУКОМА, ПЕРИМЕТРИЯ, ДИАГНОСТИЧЕСКАЯ ИНФОРМАТИВНОСТЬ, ЧУВСТВИТЕЛЬНОСТЬ И СПЕЦИФИЧНОСТЬ МЕТОДА
Περιγραφή αρχείου: text/html
-
2Academic Journal
Συγγραφείς: A. V. Sidorenkov, A. V. Govorov, A. V. Sadchenko, D. Yu. Pushkar, А. В. Сидоренков, А. В. Говоров, А. В. Садченко, Д. Ю. Пушкарь
Πηγή: Cancer Urology; Том 10, № 4 (2014); 87-95 ; Онкоурология; Том 10, № 4 (2014); 87-95 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-4
Θεματικοί όροι: чувствительность и специфичность метода, biomarker, prostate-specific antigen, [-2]proPSA, PHI index, prostate biopsy, sensitivity and specificity of the method, биомаркер, простат-специфический антиген, PHI, биопсия предстательной железы
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/403/420; Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581–92.; Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62(4):220–41.; Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37:4–66.; Cancer incidence in Sweden 2004. The National Board of Health and Welfare: Stockholm. http://sjp.sagepub.com/cgi/reprint/34/67_suppl/3.pdf.; Schroder F.H., Hugosson J., Roobol M.J. et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–28.; Andriole G.L., Crawford E.D., Grubb R.L. et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–19.; Noldus J., Graefen M., Haese A. et al. Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38; 74–78.; Лоран О.Б., Пушкарь Д.Ю., Степанов В.П., Крохотина Л.В. Дифференциальная диагностика опухолей предстательной железы с помощью определения уровня простатспецифического антигена сыворотки крови. М., 2000.; Лоран О.Б., Пушкарь Д.Ю., Франк Г.А. Простатспецифический антиген и морфологическая характеристика рака предстательной железы: Руководство для врачей. М.: МЕДпресс, 1999.; Bangma C.N., Kranse R., Blijenberg B.G., Schroder F.H. The free-to-total serum prostate specific antigen ratio for staging prostatic carcinoma. J Urology 1997;157: 544–7.; Catalona W.J. Clinical utility of measurements of free and total prostatespecific antigen (PSA). Prostate 1996; : 64–9.; Seamen E., Whang M. Prostate-specific antigen3 density (PSAD): pole in patient evaluation and management. Urol Clin North Am 1993;20:653–6.; Cuvillier O., Malavaud B. Biomarkers of aggressiveness in prostate cancer. Prostate cancer – diagnostic and therapeutic advances. November 2011;3–20.; Пушкарь Д.Ю., Говоров А.В. Маркеры рака предстательной железы. Экспериментальная и клиническая урология 2001; 2–3:19–21.; Mikolajczyk S.D., Marker K.M., Millar L.S. et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958–63.; Peter J., Unverzagt C., Krogh T.N. et al. Identification of precursor forms of prostatespecific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61:957–62.; Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59:797–802.; Chen Z., Chen H., Stamey T.A. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997;157:2166–70.; Zhang W.M., Leinonen J., Kalkkinen N. et al. Purification and characterization of different molecular forms of prostatespecific antigen in human seminal fluid. Clin Chem 1995;41:1567–73.; Mikolajczyk S.D., Grauer L.S., Millar L.S. et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710–4.; Mikolajczyk S.D., Millar L.S., Wang T.J. et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55:41–5.; Mikolajczyk S.D., Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 2003;52:86–91.; Makarov D., Isharwal S., Sokoll L. et al. Pro-prostate-specific antigen мeasurements in serum and biopsy tissue predict the need for prostate cancer treatment among men enrolled in an expectant management program. Clin Cancer Res 2009;15:7316–21.; Hori S., Blanchet J.S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSA in the detection and management of early prostate cancer. BJU International 2013;112:6.; Sokoll L.J., Chan D.W., Mikolajczyk S.D. et al. Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology 2003;61:274–6.; Khan M.A., Partin A.W., Rittenhouse H.G. et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170:723–6.; Sokoll L.J., Wang Y., Feng Z. et al. [-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008;180:539–43.; Catalona W.J., Bartsch G., Rittenhouse H.G. et al. Serum pro-prostate specific antigen cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171:2239–44.; Stephan C., Kahrs A.M., Cammann H. et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69(2):198–207.; Le B.V., Griffin C.R., Loeb S. et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010;183(4):1355–9.; Catalona W.J., Partin A.W., Sanda M.G. et al. A Multicenter study of [–2]Pro-Prostate- Specific Antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range. J Urol 2011;185:1650–5.; Jansen F.H., van Schaik R.H., Kurstjens J. et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57(6):921–7.; Guazzoni G., Nava L., Lazzeri M. et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60(2):214–22.; Lazzeri M., Haese A., Abrate A. et al. Clinical performance of serum prostatespecific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013;112(3):313–21.; Catalona W.J., Bartsch G., Rettenhous H.G. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170:2181–5.; Khan M.A., Sokoll L.J., Chan D.W. еt al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology. 2004;64(6):1160–4.; Sokoll L.J., Sanda M.G., Feng Z. et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193–200.; Vincendeau S., Ramirez J. The beckman coulter prostate health index (phi) improves diagnostic accuracy in prostate cancer detection. Eur Urol Suppl 2010;9:309.; Guazonni G., Lazzeri M., Nava L. et al. Preoperative prostate-specific antigen isoform p2PSA and its derivates, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455–66.; Filella X., Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51(4):729–39.; Houlgatte A., Vincendeau S., Desfemmes F. et al. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients]. Prog Urol 2012;22(5):279–83.; Lughezzani G., Lazzeri M., Larcher A. et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012;188:1144–50.; Lazzeri M., Briganti A., Scattoni V. et al. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 2012; 88(4):1137–4.; Lazzeri M., Haese A., de la Taille A. et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013; 63(6): 986–94.; Roobol M.J., Semjonow A., Bangma C.H. Performance of the ERSPC risk calculator for high grade prostate cancer in a clinical setting and the additional value of the Prostate Health Index (PHI®). J Urol Suppl 2011:139.; Carter H.B., Walsh P.C., Landis P., Epstein J.I. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231–4.; Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185.; Epstein J.I., Walsh P.C., Carmichael M. Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–74.; Mohler J., Bahnson R.R., Boston B. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162–200.; Tosoian J.J., Loeb S., Feng Z. et al. Association of [–2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. J Urol 2012;188: 1131–6.; https://oncourology.abvpress.ru/oncur/article/view/403
-
3Academic Journal
Πηγή: Вестник Тамбовского университета. Серия: Естественные и технические науки.
Θεματικοί όροι: ГЛАУКОМА, ПЕРИМЕТРИЯ, ДИАГНОСТИЧЕСКАЯ ИНФОРМАТИВНОСТЬ, ЧУВСТВИТЕЛЬНОСТЬ И СПЕЦИФИЧНОСТЬ МЕТОДА, 0101 mathematics, 01 natural sciences, 3. Good health
Περιγραφή αρχείου: text/html
-
4Academic Journal
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, БИОМАРКЕР, ПРОСТАТ-СПЕЦИФИЧЕСКИЙ АНТИГЕН, [-2]PROPSA, БИОПСИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, ЧУВСТВИТЕЛЬНОСТЬ И СПЕЦИФИЧНОСТЬ МЕТОДА, 3. Good health
Περιγραφή αρχείου: text/html
